Q2 2026 Results Announcement

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2026

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On July 21, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian

Securities Exchange titled “Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress” a copy of which is

attached to this Form 6-K as Exhibit 99.1.


99.1	Press release – July 21, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned, thereunto duly authorized.



		Telix Pharmaceuticals Limited

Date:	July 21, 2026	By:	/s/ Christian Krautkramer
			Name: Christian Krautkramer
			Title: Group General Counsel